Cardiac surgery is increasingly performed on elderly patients with multiple comorbid conditions, but the determinants of the relationship between cost and survival time after cardiac surgery for patients with a serious cardiac condition remain uncertain. Using the long-term outcome data of a cohort study on adult cardiac surgical patients, the relationship between cost and survival time after cardiac surgery from a hospital service perspective was determined. The total cost for each patient was estimated by the costs of the surgical procedures, intra-aortic balloon pump utilisation, operating theatre utilisation, blood products, intensive care unit stay and cumulative hospital stay up to a median follow-up time of 30 months. Of the 2131 patients considered in this study, a total cost >A$100,000 per life-year after cardiac surgery was observed only in 171 patients (8.0%, 95% confidence interval 6.9 to 9.3%). Age, Charlson Comorbidity Index and EuroSCORE were all related to the cost per life-year after cardiac surgery, but EuroSCORE (odds ratio 1.26 per score increment, 95% confidence interval 1.18 to 1.35, P=0.001) was, by far, the most important determinant and explained 32% of the variability in cost per life-year after cardiac surgery. Patients with a high EuroSCORE were associated with a substantially longer length of intensive care unit stay and cumulative hospital stay, as well as a shorter survival time after cardiac surgery compared to patients with a lower EuroSCORE. Of all the subgroups of patients examined, only patients with a EuroSCORE >5 were consistently associated with a cost >A$100,000 per life-year (cost per lifeyear $183,148, 95% confidence interval 125, 394 to 240, 902). -before surgery are important determinants of the relationship between cost and survival time after cardiac surgery. An economic analysis was conducted to determine the relative importance of these preoperative factors in a cohort of adult cardiac surgical patients.
The population of Australia is ageing. In 2012, 3.2 million people and 423,700 people were over 65 and 85 years old, constituting about 14 and 1.9% of the Australian population, respectively 1 . With advances in perioperative care, cardiac surgery is increasingly performed on elderly patients with multiple comorbidities 2 . Although survival outcome after cardiac surgery has improved substantially in the last two decades, serious complications remain common, which substantially increases the overall healthcare cost of cardiac surgery [2] [3] [4] . Increasing healthcare costs are a pressing issue in many healthcare systems 5 . A balance between the benefits of a healthcare intervention and the associated expenditure is needed to achieve a sustainable healthcare system 6 . Previous studies showed that age, poor ventricular function, complicated coronary artery disease, diabetes mellitus and re-operation were significantly associated with an increased cost of cardiac surgery 7, 8 . Although preliminary data about the relative cost-effectiveness of transcatheter aortic valve implantation and surgical aortic valve replacement in patients with severe aortic stenosis at high operative risk were available 9 , the determinants of the relationship between cost and survival time of patients after adult cardiac surgery in general have not been thoroughly studied. Due to the importance of this issue, a post hoc economic analysis of the data from a previous study on cardiac surgical patients was performed to assess the factors that are important determinants of cost in relation to survival time after cardiac surgery 10 . The hypothesis of this study was that age, comorbidities and severity of illness-as assessed by the EuroSCORE 11 -before surgery are important determinants of the relationship between cost and survival time after cardiac surgery. An economic analysis was conducted to determine the relative importance of these preoperative factors in a cohort of adult cardiac surgical patients.
METHODS

Patient characteristics and setting
This was a post hoc economic analysis of a cohort study published in this journal 10 . The original cohort study was approved by the Mount Hospital (EC69.2), Western Australian Department of Health (2012/25) and University of Notre Dame (012030F) ethics committees. The study database contained detailed data on patient characteristics, long-term survival and hospital re-admissions after surgery through the Data Linkage Unit of the Western Australian Department of Health. All patients included in this study had cardiac surgery at the Mount Hospital in Perth, Western Australia, between 2007 and 2011. The date for censoring the survival status and hospital readmissions after surgery was 31 August 2012, and the median follow-up time for the cohort was 30 months (interquartile range 17 to 43 months).
In this economic analysis, the standard recommendations on how to report an economic assessment of surgical procedures were followed 12 , and a 'hospital service perspective' was adopted using the following assumptions to estimate the cost requirements relative to survival time: . 4. The observed survival age or the mean life expectancies of a male (79.4 years old) and female (84.4 years old) in Australia, whichever was larger, were used to estimate the survival benefit of having cardiac surgery, and all survival time accumulated after surgery was attributed to benefits from surgery. 5. Ongoing hospital costs were calculated based on cumulative days of hospital re-admissions after cardiac surgery until the date of censor, and each day of hospital stay was assumed to be $1247. All costs were in Australian dollars adjusted to 2012. In this study, the main outcome was total cost per life-year gained, and no discounting was used for life-years gained in the future. The total cost per life-year gained was estimated by cost per year of life 'expected' after surgery until the average Australian life expectancy for those who survived beyond the censoring date, or cost per year of life 'observed' for those who died on or before the censoring date. A total cost <$100,000 per life-year gained was used as an arbitrary cut-off point to define whether the procedure was 'good value' (from a hospital service perspective only) 6 compared to other medical interventions 14, 15 . Although intraoperative and postoperative complications are known to increase the total cost of surgery 4 , these factors were not included because complications after cardiac surgery are often related to preoperative factors. In this study, only preoperative factors were assessed in relation Intraoperative factors: to the total cost required to achieve the expected or observed survival time, including age, Charlson Comorbidity Index (Appendix 2) and EuroSCORE (Appendix 3). These predictors were first stratified into different subgroups to assess their relationships with the cost per life-year gained after surgery. A multivariable analysis was then used to determine the relative chi-square contribution of each predictor in explaining the variability of the cost per life-year gained 16, 17 . All analyses were performed by SPSS for Windows (Version 19.0, IBM Corp., Armonk, NY, USA) or S-Plus (Version 8.0, Insightful Corp., Seattle, WA, USA), and a P value <0.05 was considered as significant.
RESULTS
Of the 2131 patients considered in this study, 28 (1.3%) patients died during the same index hospital admission for cardiac surgery and 143 (6.7%) patients died before the censoring date. The median length of ICU stay during the index admission for cardiac surgery was three days, and the total cumulative hospital stay, including hospital re-admissions, before the censoring date was 12 days (interquartile range 9 to 20) ( Table 1) .
The total cost per life-year after cardiac surgery was >$100,000 in 171 patients (8.0%, 95% confidence interval 6.9 to 9.3%). Age, Charlson Comorbidity Index and EuroSCORE were all related to the cost per life-year after cardiac surgery (Table 2 ). Of all the (Table 3) . The importance of EuroSCORE in determining cost-effectiveness could be explained by the fact that patients with a high EuroSCORE were associated with a substantially longer length of ICU stay and cumulative hospital stay as well as a shorter survival time after cardiac surgery compared to patients with a lower EuroSCORE (Figures 2a, 2b , and 2c).
DISCUSSION
This economic analysis showed that the estimated total costs per life-year after elective adult cardiac surgery for most patients (92%) were <$100,000 from a hospital service perspective. Although age, comorbidity and EuroSCORE were all related to the total cost per life-year gained after cardiac surgery, EuroSCORE was, by far, the most important determinant of the relationship between cost and survival time. The importance of EuroSCORE was seen through its associations with cumulative length of ICU and hospital stay and survival time after cardiac surgery. These findings have some clinical significance and require further consideration.
First, the estimated costs per life-year for most of our patients who had elective adult cardiac surgery were consistent with the results of other studies (<$100,000) 9 . Although the cost per life-year gained after elective cardiac surgery is more expensive than some public health initiatives (<$20,000 per lifeyear after the intervention) 18, 19 , total hip or knee joint arthroplasty (<$10,000 per quality-adjusted lifeyear after surgery) 20 and implantation of a cardioverter defibrillator for patients who have a previous myocardial infarction with a low ejection fraction ($54,100 per life-year after implantation of the device) 6 , it is still substantially lower than for some emergency therapies used in ICUs, such as factor VIIa for critical bleeding requiring massive transfusion 14 and decompressive craniectomy for severe traumatic brain injury 15 . The cost per life-year after cardiac surgery would possibly be lower if the costs of employing salaried specialists, instead of MBS item costs, were used to estimate the total cost of delivering the elective cardiac surgical services. Second, the severity of the cardiac condition of the patients, as measured by the EuroSCORE, has a substantial bearing on the subsequent healthcare requirements of the patients after cardiac surgery and, hence, the cost per life-year after the procedure. Other than being used as a tool for risk adjustment in quality assurance, EuroSCORE may also be useful to assist clinicians and policymakers to appreciate other issues related to cardiac surgery, including subsequent length of hospital stay, risk of hospital re-admission and cost per life-year gained after the procedure. In assessing cost per life-year after a new cardiac surgical procedure, it may be important to compare the cost per life-year after the new procedure to that after established procedures for patients with different EuroSCOREs because cost per life-year after a cardiac surgical procedure is significantly related to the EuroSCORE of the patients. It has to be emphasised that the results of this study should only be used to appreciate the costs of cardiac surgery from a hospital service perspective and how its associated costs per life-year after surgery compare to other common medical therapies. Because the confidence interval of the cost per life-year after surgery in many subgroups of patients was wide, the applicability of the results of this study to individual patients was very limited, and the data should not be used to predict costs for any individual patient.
Third, medical comorbidities have been shown previously to have a substantial impact on the shortterm and long-term outcomes of hospitalised patients, including critically ill patients [21] [22] [23] [24] . The data on the same cohort of patients of this study also showed that the Charlson Comorbidity Index had a substantial effect on long-term survival and also complications after cardiac surgery 10 , including acute kidney injury requiring dialysis, massive transfusion, venous thromboembolism and stroke. Although a strong association between the Charlson Comorbidity Index and cost per life-year in this study was not observed, the importance of comorbidities in determining the relationship between cost and survival time after cardiac surgery should not be completely discarded. This is because EuroSCORE includes weightings for a number of comorbidities, including congestive heart failure or low left ventricular ejection fraction, pulmonary hypertension, chronic pulmonary disease requiring bronchodilators or corticosteroids, neurological disease that affects mobility, and peripheral vascular disease (Appendix 3). This might have concealed the effect of the Charlson Comorbidity Index on the total cost per life-year gained after cardiac surgery.
This study has some limitations. The analyses of this study were based on the assumption that all the survival time accrued after surgery was attributed to the cardiac surgical procedure. This gives us the 'best case scenario' for considering what to expect when cardiac surgery is considered as a life-saving procedure. It is very likely that many of these patients would have survived for a period of time just by using medical therapies alone. Hence, estimation of the incremental cost-effectiveness of cardiac surgery compared to medical therapies alone was not possible. In addition, only cost per life-year after cardiac surg- ery from a hospital service perspective was considered. Data on patients' and their relatives' productivity gain (e.g. ability to resume work or become less dependent on carers) or loss (e.g. patients' and their families' sick leave requirements due to surgery or complications leading to hospital re-admissions, or long-term disability due to complications after surgery) related to surgery are also important. Such data was not available and, hence, the cost per lifeyear after cardiac surgery from a societal perspective remains uncertain. Furthermore, the follow-up time of the cohort was relatively short (with a median follow-up time of 30 months), and it is possible that cardiac surgery could be less favourable if a substantial number of patients died after 30 months of followup. Finally, the quality of life data of patients after cardiac surgery is important and will have significant bearing on the balance between costs and benefits after cardiac surgery, as well as the cost per qualityadjusted life-year after cardiac surgery.
In summary, this economic analysis showed that the total cost per life-year after surgery for most patients who had elective adult cardiac surgery was <$100,000 from a hospital service perspective. Age, comorbidity and EuroSCORE were all related to the total cost per life-year after elective cardiac surgery, but EuroSCORE appeared to be the most important. Relative cost and cost-effectiveness per quality-adjusted life-year after different cardiac surgical procedures for elderly patients with severe comorbidities, however, remains uncertain and warrants further investigation.
